article thumbnail

CMS proposes issuing separate payment for diagnostic radiopharmaceuticals in 2025

Radiology Business

For years, the agency has packaged payment for nuclear imaging agents with the procedure, but this has created a barrier for those who require pricier new drugs.

article thumbnail

CMS' MPFS 2025 final rule includes colorectal cancer screening

AuntMinnie

Centers for Medicare and Medicaid Services (CMS) has released its final rule for the 2025 Medicare Physician Fee Schedule (MPFS), which includes coverage of colorectal cancer screening with CT colonography (CTC) for the first time. In the end, this translates to a finalized 2025 MPFS conversion factor of $32.35, a decrease of 2.8%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Nuclear cardiology could face cuts in 2025

AuntMinnie

Nuclear cardiologists could see significant reductions in Medicare reimbursements in 2025, according to a leading expert. Ultimately, there are “many unknowns” to be explored in the next few months – implications regarding the unknown cost of new diagnostic radiopharmaceuticals, for instance – and the ASNC is in continuing talks with the CMS.

article thumbnail

CMS proposes new coverage for PET imaging agents

AuntMinnie

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

article thumbnail

CMS Adjusts Nuclear Medicine Reimbursement Policy, Expanding Access to Life-Saving Scans

Imaging Technology

Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures. tim.hodson Thu, 11/07/2024 - 11:25 Nov.

article thumbnail

New guidelines cover theranostics for brain tumors

AuntMinnie

These SSTRs can be targeted both with gallium-68 (Ga-68) imaging agents and therapeutic lutetium-177 (Lu-177) radiopharmaceuticals using a so-called theranostics approach. Meningiomas are the most common primary adult intracranial tumors and most meningiomas show high expression of somatostatin receptors (SSTRs). In the U.S.,

article thumbnail

NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors

Imaging Technology

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.